Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Analytic Gradients for the Spin-Flip ORMAS-CI Method: Optimizing Minima, Saddle Points, and Conical Intersections.

Mato J, Gordon MS.

J Phys Chem A. 2019 Jan 15. doi: 10.1021/acs.jpca.8b11569. [Epub ahead of print]

PMID:
30645115
2.

Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.

Melvin GA, Finnin L, Taffe J, Dudley AL, Klimkeit EI, Gordon MS, Tonge B.

Clin Child Psychol Psychiatry. 2019 Jan 12:1359104518822681. doi: 10.1177/1359104518822681. [Epub ahead of print]

PMID:
30638065
3.

Pharmacotherapy for opioid addiction in community corrections.

Schwartz RP, Mitchell MM, O'Grady KE, Kelly SM, Gryczynski J, Mitchell SG, Gordon MS, Jaffe JH.

Int Rev Psychiatry. 2018 Dec 6:1-19. doi: 10.1080/09540261.2018.1524373. [Epub ahead of print]

PMID:
30522370
4.

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.

Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P Jr.

Clin Lung Cancer. 2018 Oct 24. pii: S1525-7304(18)30267-5. doi: 10.1016/j.cllc.2018.10.006. [Epub ahead of print]

5.

Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.

Soares WE 3rd, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD.

Drug Alcohol Depend. 2019 Jan 1;194:482-486. doi: 10.1016/j.drugalcdep.2018.10.035. Epub 2018 Dec 3.

PMID:
30522048
6.

A Quasi-Atomic Analysis of Three-Center Two-Electron Zr-H-Si Interactions.

Duchimaza Heredia JJ, Sadow AD, Gordon MS.

J Phys Chem A. 2018 Nov 27. doi: 10.1021/acs.jpca.8b09530. [Epub ahead of print]

PMID:
30481021
7.

Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations.

Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA.

Drug Alcohol Depend. 2019 Jan 1;194:59-68. doi: 10.1016/j.drugalcdep.2018.10.003. Epub 2018 Oct 23.

PMID:
30412898
8.

Application of a semi-empirical dispersion correction for modeling water clusters.

De Silva N, Adreance MA, Gordon MS.

J Comput Chem. 2019 Jan 15;40(2):310-315. doi: 10.1002/jcc.25596. Epub 2018 Oct 20.

PMID:
30368848
9.

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS.

Invest New Drugs. 2018 Sep 28. doi: 10.1007/s10637-018-0668-8. [Epub ahead of print]

PMID:
30264293
10.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P.

JAMA Oncol. 2018 Sep 13. doi: 10.1001/jamaoncol.2018.4224. [Epub ahead of print]

PMID:
30242306
11.

Solvation of the Glycyl Radical.

Chan B, Rintelman J, Wood GPF, Radom L, Gordon MS.

J Phys Chem A. 2018 Sep 13;122(36):7212-7217. doi: 10.1021/acs.jpca.8b06833. Epub 2018 Aug 30.

PMID:
30160481
12.

Proton Transfer in 1,2,4-Triazolium Dinitramide: Effect of Aqueous Microsolvation.

Conrad JA, Pruitt SR, Gordon MS.

J Phys Chem A. 2018 Sep 20;122(37):7443-7454. doi: 10.1021/acs.jpca.8b06348. Epub 2018 Sep 10.

PMID:
30129759
13.

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC.

Eur J Cancer. 2018 Sep;101:201-209. doi: 10.1016/j.ejca.2018.06.031. Epub 2018 Aug 1.

PMID:
30077125
14.

Perceived Invalidation in Adolescent Borderline Personality Disorder: An Investigation of Parallel Reports of Caregiver Responses to Negative Emotions.

Bennett C, Melvin GA, Quek J, Saeedi N, Gordon MS, Newman LK.

Child Psychiatry Hum Dev. 2018 Aug 1. doi: 10.1007/s10578-018-0833-5. [Epub ahead of print]

PMID:
30069665
15.

Trajectories of depressive symptoms from adolescence to emerging adulthood: The influence of parents, peers, and siblings.

Finan LJ, Ohannessian CM, Gordon MS.

Dev Psychol. 2018 Aug;54(8):1555-1567. doi: 10.1037/dev0000543.

PMID:
30047776
16.

Evaluating the Feasibility and Effectiveness of an Australian Safety Planning Smartphone Application: A Pilot Study Within a Tertiary Mental Health Service.

Melvin GA, Gresham D, Beaton S, Coles J, Tonge BJ, Gordon MS, Stanley B.

Suicide Life Threat Behav. 2018 Jul 12. doi: 10.1111/sltb.12490. [Epub ahead of print]

PMID:
29999193
17.

Benchmarking of the R-7 Anisotropic Dispersion Energy Term on the S22 Dimer Test Set.

Schoeberle L, Guidez EB, Gordon MS.

J Phys Chem A. 2018 Jul 26;122(29):6100-6108. doi: 10.1021/acs.jpca.8b04451. Epub 2018 Jul 17.

PMID:
29965762
18.

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA.

Clin Cancer Res. 2018 Nov 15;24(22):5525-5533. doi: 10.1158/1078-0432.CCR-18-0494. Epub 2018 May 29.

PMID:
29844129
19.

Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes.

Gordon MS, Blue TR, Couvillion K, Schwartz RP, O'Grady KE, Fitzgerald TT, Vocci FJ.

Drug Alcohol Depend. 2018 Jul 1;188:232-238. doi: 10.1016/j.drugalcdep.2018.04.010. Epub 2018 May 12.

PMID:
29783095
20.

An investigation of the mentalization-based model of borderline pathology in adolescents.

Quek J, Bennett C, Melvin GA, Saeedi N, Gordon MS, Newman LK.

Compr Psychiatry. 2018 Jul;84:87-94. doi: 10.1016/j.comppsych.2018.04.005. Epub 2018 Apr 14.

PMID:
29727808
21.

Benchmarking the Effective Fragment Potential Dispersion Correction on the S22 Test Set.

Kim S, Kaliszewski CM, Guidez EB, Gordon MS.

J Phys Chem A. 2018 Apr 26;122(16):4076-4084. doi: 10.1021/acs.jpca.7b11628. Epub 2018 Apr 13.

PMID:
29601202
22.

Quasi-Atomic Bonding Analysis of Xe-Containing Compounds.

Duchimaza Heredia JJ, Ruedenberg K, Gordon MS.

J Phys Chem A. 2018 Apr 5;122(13):3442-3454. doi: 10.1021/acs.jpca.8b00115. Epub 2018 Mar 26.

PMID:
29533624
23.

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW.

Cancer. 2018 May 15;124(10):2174-2183. doi: 10.1002/cncr.31304. Epub 2018 Mar 13.

24.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
25.

Mentalization in Adolescents With Borderline Personality Disorder: A Comparison With Healthy Controls.

Quek J, Melvin GA, Bennett C, Gordon MS, Saeedi N, Newman LK.

J Pers Disord. 2018 Feb 22:1-19. doi: 10.1521/pedi_2018_32_336. [Epub ahead of print]

PMID:
29469664
26.

Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision.

Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, O'Brien CP.

J Empir Res Hum Res Ethics. 2018 Apr;13(2):160-172. doi: 10.1177/1556264618755243. Epub 2018 Feb 20.

PMID:
29460668
27.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.

Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.

PMID:
29431699
28.

A general spin-complete spin-flip configuration interaction method.

Mato J, Gordon MS.

Phys Chem Chem Phys. 2018 Jan 24;20(4):2615-2626. doi: 10.1039/c7cp06837a.

PMID:
29319079
29.

A Randomized Controlled Trial of Intensive Case Management (Project Bridge) for HIV-Infected Probationers and Parolees.

Gordon MS, Crable EL, Carswell SB, Leopold J, Hodo-Powell J, McKenzie M, Rich JD.

AIDS Behav. 2018 Mar;22(3):1030-1038. doi: 10.1007/s10461-017-2016-y.

PMID:
29273946
30.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF.

Br J Clin Pharmacol. 2018 Apr;84(4):764-775. doi: 10.1111/bcp.13488. Epub 2018 Jan 23.

PMID:
29243287
31.

Identification and Characterization of Molecular Bonding Structures by ab initio Quasi-Atomic Orbital Analyses.

West AC, Duchimaza-Heredia JJ, Gordon MS, Ruedenberg K.

J Phys Chem A. 2017 Nov 22;121(46):8884-8898. doi: 10.1021/acs.jpca.7b07054. Epub 2017 Nov 14.

PMID:
29135255
32.

Dispersion Interactions in QM/EFP.

Slipchenko LV, Gordon MS, Ruedenberg K.

J Phys Chem A. 2017 Dec 14;121(49):9495-9507. doi: 10.1021/acs.jpca.7b05875. Epub 2017 Dec 5.

PMID:
29120179
33.

Clinician perspectives and practices regarding the use of exercise in the treatment of adolescent depression.

Radovic S, Melvin GA, Gordon MS.

J Sports Sci. 2018 Jun;36(12):1371-1377. doi: 10.1080/02640414.2017.1383622. Epub 2017 Sep 25.

PMID:
28945524
34.

Effect of Boron Clusters on the Ignition Reaction of HNO3 and Dicynanamide-Based Ionic Liquids.

Schmidt MW, Gordon MS.

J Phys Chem A. 2017 Oct 19;121(41):8003-8011. doi: 10.1021/acs.jpca.7b07996. Epub 2017 Oct 6.

PMID:
28922914
35.

Reflective function mediates the relationship between emotional maltreatment and borderline pathology in adolescents: A preliminary investigation.

Quek J, Newman LK, Bennett C, Gordon MS, Saeedi N, Melvin GA.

Child Abuse Negl. 2017 Oct;72:215-226. doi: 10.1016/j.chiabu.2017.08.008. Epub 2017 Aug 23.

PMID:
28841475
36.

Can Orbitals Really Be Observed in Scanning Tunneling Microscopy Experiments?

Pham BQ, Gordon MS.

J Phys Chem A. 2017 Jul 6;121(26):4851-4852. doi: 10.1021/acs.jpca.7b05789. No abstract available.

PMID:
28679210
37.

Avatar-assisted therapy: a proof-of-concept pilot study of a novel technology-based intervention to treat substance use disorders.

Gordon MS, Carswell SB, Schadegg M, Mangen K, Merkel K, Tangires S, Vocci FJ.

Am J Drug Alcohol Abuse. 2017 Sep;43(5):518-524. doi: 10.1080/00952990.2017.1280816. Epub 2017 Feb 17.

PMID:
28635345
38.

The daily progress system: A proof of concept pilot study of a recovery support technology tool for outpatient substance abuse treatment.

Carswell SB, Gordon MS, Gryczynski J, Tangires SA.

Am J Drug Alcohol Abuse. 2018;44(3):294-301. doi: 10.1080/00952990.2017.1329311. Epub 2017 May 30.

39.

Cohort profile: seek, test, treat and retain United States criminal justice cohort.

Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM.

Subst Abuse Treat Prev Policy. 2017 May 16;12(1):24. doi: 10.1186/s13011-017-0107-4.

40.

Relativistic ab Initio Accurate Atomic Minimal Basis Sets: Quantitative LUMOs and Oriented Quasi-Atomic Orbitals for the Elements Li-Xe.

Schoendorff G, West AC, Schmidt MW, Ruedenberg K, Wilson AK, Gordon MS.

J Phys Chem A. 2017 May 11;121(18):3588-3597. doi: 10.1021/acs.jpca.7b01916. Epub 2017 Apr 26.

PMID:
28406302
41.

Publications of Mark S. Gordon.

Gordon MS.

J Phys Chem A. 2017 Apr 13;121(14):2721-2739. doi: 10.1021/acs.jpca.7b00176. No abstract available.

PMID:
28403617
42.

Students and Co-workers of Mark S. Gordon.

Gordon MS.

J Phys Chem A. 2017 Apr 13;121(14):2719-2720. doi: 10.1021/acs.jpca.7b00180. No abstract available.

PMID:
28403615
43.

Dispersion Interactions in Water Clusters.

Guidez EB, Gordon MS.

J Phys Chem A. 2017 May 18;121(19):3736-3745. doi: 10.1021/acs.jpca.6b11403. Epub 2017 May 8.

PMID:
28379001
44.

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.

Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM.

Invest New Drugs. 2017 Oct;35(5):627-633. doi: 10.1007/s10637-017-0444-1. Epub 2017 Mar 10.

45.

Multipole Moments in the Effective Fragment Potential Method.

Bertoni C, Slipchenko LV, Misquitta AJ, Gordon MS.

J Phys Chem A. 2017 Mar 9;121(9):2056-2067. doi: 10.1021/acs.jpca.7b00682. Epub 2017 Feb 27.

PMID:
28211686
46.

Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium.

Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA.

AIDS Behav. 2017 Oct;21(10):2945-2957. doi: 10.1007/s10461-017-1722-9.

47.

ParFit: A Python-Based Object-Oriented Program for Fitting Molecular Mechanics Parameters to ab Initio Data.

Zahariev F, De Silva N, Gordon MS, Windus TL, Dick-Perez M.

J Chem Inf Model. 2017 Mar 27;57(3):391-396. doi: 10.1021/acs.jcim.6b00654. Epub 2017 Feb 23.

PMID:
28169538
48.

Intrinsic Resolution of Molecular Electronic Wave Functions and Energies in Terms of Quasi-atoms and Their Interactions.

West AC, Schmidt MW, Gordon MS, Ruedenberg K.

J Phys Chem A. 2017 Feb 9;121(5):1086-1105. doi: 10.1021/acs.jpca.6b10911. Epub 2017 Jan 30.

PMID:
28134532
49.

A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE, Fitzgerald TT, Vocci FJ.

Drug Alcohol Depend. 2017 Mar 1;172:34-42. doi: 10.1016/j.drugalcdep.2016.11.037. Epub 2017 Jan 11.

50.

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.

Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI.

Br J Cancer. 2017 Feb 14;116(4):432-440. doi: 10.1038/bjc.2016.419. Epub 2017 Jan 19.

Supplemental Content

Loading ...
Support Center